@article{0a64118f80f94f8ea1a1604e736920d5,
title = "Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential",
abstract = "The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.",
keywords = "Ebola virus, MERS-CoV, SARS-CoV, SARS-CoV-2 (COVID-19), Zika virus, broad antiviral agents, coronavirus, flavivirus, human adenovirus, niclosamide",
author = "Jimin Xu and Shi, {Pei Yong} and Hongmin Li and Jia Zhou",
note = "Funding Information: This work was supported by grants R01 AI131669 and R21 AI134568 from the National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health, John D. Stobo, the M. D. Distinguished Chair Endowment Fund, and the John Sealy Memorial Endowment Fund at UTMB. P.-Y.S. was supported by NIH grants AI142759, AI127744, and AI136126, and awards from the Kleberg Foundation, John S. Dunn Foundation, Amon G. Carter Foundation, Gilson Longenbaugh Foundation, and Summerfield Robert Foundation. We thank Ms. Xiuna Yang in Prof. Zihe Rao{\textquoteright}s laboratory for her courtesy in sharing the PDB file of SARS-CoV-2 (2019-nCoV) 3CL protease (PDB ID: 6LU7 ). Publisher Copyright: {\textcopyright} 2020 American Chemical Society. All rights reserved.",
year = "2020",
month = may,
day = "8",
doi = "10.1021/acsinfecdis.0c00052",
language = "English (US)",
volume = "6",
pages = "909--915",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",
number = "5",
}